Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Practice Point
  • Published:

The battle between anti-cyclic citrullinated peptide and rheumatoid factor tests—a winner at last?

Nature Clinical Practice Rheumatology volume 3, pages 696–697 (2007)Cite this article

boxed-textNishimura K et al. (2007) Meta-analysis: diagnostic accuracy of anti-cyclic citrullinated peptide antibody and rheumatoid factor for rheumatoid arthritis. Ann Int Med 146: 797–808

Anti-CCP assays have higher specificity and comparable sensitivity to IgM RF assays for the diagnosis of RA; measuring anti-CCP is, therefore, the best first-line diagnostic tool, and the added value of determining IgM RF levels is debatable

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Lard LR et al. (2001) Early versus delayed treatment in patients with recent-onset rheumatoid arthritis: comparison of two cohorts who received different treatment strategies. Am J Med 111: 446–451

    Article  CAS  Google Scholar 

  2. Schellekens GA et al. (1998) Citrulline is an essential constituent of antigenic determinants recognized by rheumatoid arthritis-specific autoantibodies. J Clin Invest 101: 273–281

    Article  CAS  Google Scholar 

  3. Coenen D et al. (2007) Technical and diagnostic performance of 6 assays for the measurement of citrullinated protein/peptide antibodies in the diagnosis of rheumatoid arthritis. Clin Chem 53: 498–504

    Article  CAS  Google Scholar 

  4. Kallberg H et al. (2007) Gene-gene and gene-environment interactions involving HLA-DRB1, PTPN22, and smoking in two subsets of rheumatoid arthritis. Am J Hum Genet 80: 867–875

    Article  Google Scholar 

Download references

Acknowledgements

The synopsis was written by Jasmine Farsarakis, Assoiate Editor, Nature Clinical Practice.

Author information

Authors and Affiliations

  1. both at the Department of Rheumatology, D van der Woude is a Resident in Internal Medicine and a Research Fellow, and TWJ Huizinga is a Professor of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands.,

    Diane van der Woude & Tom WJ Huizinga

Authors
  1. Diane van der Woude
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Tom WJ Huizinga
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Diane van der Woude.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

van der Woude, D., Huizinga, T. The battle between anti-cyclic citrullinated peptide and rheumatoid factor tests—a winner at last?. Nat Rev Rheumatol 3, 696–697 (2007). https://doi.org/10.1038/ncprheum0654

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncprheum0654

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing